Replies to post #2552 on RedHill Biopharma Ltd (RDHL)

[midastouch017]

RedHill Biopharma's opaganib shows encouraging action in animal study

Dec. 15, 2020 10:51 AM ETRedHill Biopharma Ltd. (RDHL)By: Vandana Singh, SA News Editor

RedHill Biopharma (RDHL +3.9%) has announced promising preliminary results from a preclinical study within which opaganib, an orally administered sphingosine kinase 2 selective inhibitor, demonstrated a reduction of thrombosis (blood clotting) in an acute respiratory distress syndrome (ARDS) animal models.

Opaganib has also been shown to inhibit SARS-CoV-2 viral replication as well as pro-inflammatory markers in relevant preclinical models.

Top-line data from an ongoing global Phase 2/3 study of opaganib in patients with severe COVID-19, is expected in Q1/2021 with potential global emergency use applications to follow.